By Momo Yamamoto, Senior Investor Research Analyst, LSN
Life Science Nation is pleased to announce the launch of RESI Asia Japan, a new conference created in collaboration with the Kobe Biomedical Innovation Cluster (KBIC), Japan’s largest biomedical cluster.
Taking place on April 13, 2027, at the ANA InterContinental Tokyo, RESI Asia Japan will bring together early-stage life science companies, investors, strategic partners, and regional stakeholders for a day of in-person programming, followed by virtual partnering opportunities.
The event expands Life Science Nation’s global platform for connecting innovative companies with the capital and strategic relationships needed to advance their technologies. For companies seeking to enter Japan, build international partnerships, or connect with new sources of capital, RESI Asia Japan provides a direct pathway into one of the world’s most important life science markets.
Why Japan Matters for Life Science Companies
Japan is home to major global pharmaceutical companies, including Takeda, Astellas, Daiichi Sankyo, Eisai, Chugai, and Ono. These organizations are active participants in licensing, acquisition, and external innovation partnerships, creating meaningful opportunities for early-stage companies with differentiated technologies and strong development plans.
A Japan rights deal can provide early non-dilutive capital, strategic validation, and a foundation for broader international growth. Japan also offers deep clinical trial and CRO capacity, as well as a regulatory environment with meaningful opportunities for regenerative medicine and cell and gene therapy development.
Yet the market can be difficult to access from outside the region. Identifying the right partners, arranging initial meetings, understanding the regulatory landscape, and navigating local business relationships all require a focused approach. RESI Asia Japan is designed to help bridge that gap.
A Partnership Built for Global Connection
RESI Asia Japan is the culmination of a three-conference collaboration between Life Science Nation and KBIC. KBIC served as a Title Sponsor at RESI Boston in September 2026 and will continue its partnership at RESI JPM in January 2027, leading into the inaugural Tokyo event in April.
For companies participating across the series, the partnership creates three opportunities to engage with the LSN network over seven months, while building visibility with investors, strategic partners, and life science stakeholders across the United States and Japan.
Beyond the conference itself, Life Science Nation and KBIC are working to strengthen the commercialization pathway for Japanese life science companies through entrepreneur education, company preparation, capital formation, and international business development.
Registration Is Open
RESI Asia Japan offers a 5-Day Hybrid format, including the in-person conference in Tokyo and virtual programming, as well as a 4-Day Virtual Partnering format.
| Japan-base Registration (JPY) |
| Non-Japan-base Registration (USD) |
Explore the RESI 2027 Series
RESI Asia Japan is part of Life Science Nation’s 2027 global conference series, creating multiple opportunities throughout the year to connect with investors, strategic partners, and life science innovators.
- RESI JPM: January 11 to 12 in San Francisco, with virtual partnering on January 13, 18, and 19
- RESI Asia Japan: April in Tokyo
- RESI Philadelphia: June
- RESI Boston: September
Learn more about the full RESI 2027 series at RESIConference.com.
